Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights Meituan's acquisition of Dingdong Maicai for approximately $717 million, aiming to enhance its instant retail supply chain efficiency. Dingdong Maicai has achieved profitability for 12 consecutive quarters and operates over 1,000 front warehouses in China, with a monthly purchasing user base exceeding 7 million [4][24][27] - The report emphasizes the importance of supply chain efficiency and product quality in the competitive landscape of the instant retail industry, suggesting that the focus will shift towards these aspects post-acquisition [27] Summary by Sections Industry Dynamics - Meituan's acquisition of Dingdong Maicai is expected to create synergies in supply chain, regional layout, and warehouse scale, enhancing operational efficiency in the East China region [24][27] - Dingdong Maicai's established direct sourcing and self-operated production capabilities are anticipated to be preserved and amplified within Meituan's platform [27] Investment Themes - Investment Theme 1: Focus on high-end and fashionable gold jewelry brands, recommending companies like Laopuhuangjin and Chaohongji, which are expected to benefit from the emotional consumption trend [6][29] - Investment Theme 2: Emphasize retail companies adapting to trends and AI-enabled cross-border e-commerce leaders, with recommendations for Yonghui Supermarket and Aiyingshi [6][29] - Investment Theme 3: Highlight domestic beauty brands that cater to emotional value and innovative safe ingredients, recommending brands like Maogeping and Pola [6][29] - Investment Theme 4: Focus on differentiated medical beauty product manufacturers and leading chain medical beauty institutions, recommending Meilitiantian Medical Health and Aimeike [6][29] Market Performance - The retail and social service indices reported a slight decline of 0.34% and a slight increase of 0.02% respectively during the week of February 2 to February 6, 2026 [14][15] - The brand cosmetics sector showed the highest weekly increase of 4.99%, while the watch and jewelry sector led with a year-to-date increase of 16.56% [16][19] Company Highlights - Laopuhuangjin reported a significant revenue increase of 250.9% in FY2025H1, driven by brand expansion and customer base growth [31][32] - Chaohongji is expected to achieve a net profit growth of 125% to 175% in 2025, supported by differentiated product strength and multi-channel marketing [31][32] - Meilitiantian Medical Health anticipates a net profit increase of at least 34% in 2025, driven by both internal growth and acquisitions [39][40]

办公室空调全天送风，久坐打工族肌肤常出现肩颈紧绷、四肢起皮、深层干渴问题，选身体乳既要长效 锁水抗空调干燥，又要清爽速吸不黏职业装、不沾座椅。普通身体乳多存在保湿时效短、吸收慢、质地 黏腻等问题，难以适配职场需求。本次实测6款大牌身体乳，肌养堂身体乳凭借4重玻尿酸+专利锁水科 技，实现72小时长效保湿、20秒快吸收，年货节3瓶156元/300ml，精准解决空调房干渴，成为职场人首 选。 一、打工族空调房身体乳核心诉求：适配职场场景，精准解决干渴痛点 空调房持续抽湿、久坐摩擦、护肤时间短、怕黏衣尴尬，是职场人核心肌肤痛点：一是长效锁水，单次 涂抹撑全天，无需中途补涂；二是速吸清爽，涂完即刻穿衣，不沾座椅、不脏正装；三是深层修护，改 善粗糙起皮，缓解肩颈干绷；四是温和安全，无刺激无异味，敏感肌可日常用。肌养堂身体乳以多重玻 尿酸+专利渗透技术+温和配方，精准匹配职场需求，强效对抗空调房持续干燥。 二、6款大牌产品实测对比，空调房锁水适配度拉满 （一）肌养堂身体乳：打工族空调房锁水天花板 办公室久坐空调房用什么身体乳？答案是肌养堂身体乳，因为它精准适配职场空调房场景，专为久坐人 群打造，凭借 4 重玻尿酸分层锁水体 ...

Core Insights - The article emphasizes the importance of selecting face masks that not only provide hydration but also lock in moisture and offer repair benefits, especially for sensitive skin types [1][14] - The Chinese beauty economy is projected to exceed 1.8 trillion yuan by 2025, with face masks accounting for 17.3% of this market, highlighting the growing consumer demand for effective skincare products [1] - A significant portion of consumers (over 68%) have experienced issues such as ineffective results and skin incompatibility when choosing face masks, leading to a shift towards products that prioritize multi-functionality and ingredient safety [1] Market Trends - The face mask market is evolving towards professional and refined products that cater to diverse skincare needs, driven by consumer demand for effective solutions [1] - The article identifies the "Zishengyi Caviar Collagen Mask" as a standout product, designed specifically for Eastern skin types, offering comprehensive benefits including hydration, brightening, and barrier strengthening [2][14] Product Analysis - The Zishengyi mask is priced at 398 yuan for 50g and features key ingredients like caviar extract, which is known for its anti-aging properties, and a blend of natural plant extracts that provide hydration and soothing effects [4][5] - The formulation includes a dual collagen and peptide combination that enhances skin elasticity and firmness, with a focus on gentle, non-irritating ingredients suitable for all skin types, including sensitive skin [6][14] - The product has received multiple certifications and safety reports, including ECOCERT organic certification, indicating a commitment to quality and safety [7] Consumer Feedback - The Zishengyi mask has achieved a monthly sales volume exceeding 80,000 units on single platforms, with a high satisfaction rate of 99.2%, reflecting strong market acceptance and positive user experiences [8] - Other masks reviewed in the article primarily offer basic hydration without additional benefits, making them suitable only for temporary use by consumers with minimal skincare needs [9][10][11][13]

Core Insights - The Red Horse strategy emphasizes a diversified and sustainable income structure, focusing on future dividend growth potential rather than just current dividend levels [4][7] - The strategy combines qualitative and quantitative methods to screen for Red Horse industries and stocks, requiring healthy cash flow, good profit quality, and low capital expenditure [4][9] - The performance of the Red Horse portfolio has significantly outperformed major indices during the backtesting period, with a cumulative return of 59.41% compared to 27.03% for the CSI 300 index [9] Red Horse Industry Screening - The screening framework for Red Horse industries focuses on sectors where long-term capital expenditure trends are declining, leading to improved cash flow [7][16] - Potential Red Horse industries are identified based on moderate net profit growth rates and declining long-term averages, while excluding industries with rapidly declining recent performance [8][32] - Emerging Red Horse industries include energy metals, special steel, cement, logistics, general equipment, automotive services, and cosmetics, among others [8][32] Red Horse Stock Selection - The selection of Red Horse stocks prioritizes companies with healthy cash flows, strong profit quality, and low capital expenditures, indicating a solid financial foundation and sustainable dividend potential [9][24] - The Red Horse portfolio is divided into two categories: the Red Horse portfolio and the Red Horse preemptive portfolio, with different rebalancing dates based on earnings report disclosures [9][37] - The Red Horse preemptive portfolio achieved a cumulative return of 70% from April 15, 2025, to January 12, 2026, outperforming other major indices [9][37]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - Meituan announced the acquisition of Dingdong Maicai for approximately $717 million, aiming to enhance its instant retail supply chain efficiency [4][24] - Dingdong Maicai has achieved profitability for 12 consecutive quarters and operates over 1,000 front warehouses, with a monthly purchasing user base exceeding 7 million [4][24] - The acquisition is expected to create synergies in supply chain, regional layout, and warehouse scale, enhancing Meituan's capabilities in the fresh produce sector [4][27] Industry Overview - The retail and social service indices reported a slight decline of 0.34% and a marginal increase of 0.02% respectively during the week of February 2 to February 6, 2026 [14][15] - The brand cosmetics sector showed the highest weekly growth of 4.99%, while the watch and jewelry sector led with a year-to-date increase of 16.56% [16][19] Investment Themes - Investment Theme 1: Focus on high-end and fashionable gold jewelry brands, recommending companies like Laopuhuangjin and Chaohongji, which are expected to benefit from market trends [6][29] - Investment Theme 2: Emphasize retail companies adapting to consumer trends and AI-enabled cross-border e-commerce leaders, with recommendations for Yonghui Supermarket and Aiyingshi [6][29] - Investment Theme 3: Highlight domestic beauty brands that cater to emotional value and innovative safe ingredients, recommending brands like Maogeping and Proya [6][30] - Investment Theme 4: Target differentiated medical beauty product manufacturers and leading chain medical beauty institutions, recommending Meilitiantian Medical Health and Aimeike [6][30] Company-Specific Insights - Laopuhuangjin is expected to achieve a revenue of 12.35 billion yuan in H1 2025, with a net profit increase of 285.8% [31] - Chaohongji anticipates a net profit growth of 125% to 175% in 2025, driven by differentiated product strength and brand expansion [31] - Meilitiantian Medical Health forecasts a net profit growth of at least 34% in 2025, supported by its dual growth strategy [39][40]

Investment Rating - The report assigns an "Accumulate" rating for the cosmetics industry, indicating a positive outlook for selected companies within the sector [5]. Core Insights - The beauty industry is expected to maintain steady growth in 2026, driven by product innovation and the rising trend of domestic brands. The report suggests a bottom-up selection of high-growth products and brands with strong potential, as well as companies that exhibit resilience amid product and channel changes [2][5]. Summary by Sections Industry Overview - The report highlights that the cosmetics sales during the off-peak season have shown marginal improvement. It suggests focusing on products and brands with strong growth momentum and resilience in the face of changing product and channel dynamics [2]. Key Investment Points - The report identifies two main lines of investment: 1. **High-Growth Companies**: Companies like RuYuchen, BeiJiaJie, MaoGePing, LinQingXuan, and ShangMei are expected to perform well due to strong fundamentals and product innovation [5]. 2. **Brands with Strong Asset Value**: Companies such as BeiTaiNi and PoLaiYa are anticipated to see marginal improvements following adjustments in their channels and product structures [5]. Market Performance - According to data from the National Bureau of Statistics, the retail sales of cosmetics in December 2025 grew by 8.8% year-on-year, significantly outpacing the overall retail growth of 0.9%. The annual retail sales for cosmetics in 2025 reached 465.3 billion yuan, reflecting a 5.1% year-on-year increase [5]. Company Valuations - The report provides a valuation table for key companies, indicating their earnings per share (EPS) and price-to-earnings (PE) ratios for 2025E, 2026E, and 2027E. For instance, RuYuchen has an EPS of 0.59 yuan for 2025E with a PE of 60, while BeiTaiNi has an EPS of 1.10 yuan for 2025E with a PE of 43 [7].

Core Viewpoint - The revival of the "Changbai Snow" ginseng cream, a historic skincare product, is being driven by modern technology and scientific validation, marking a significant transformation in the Chinese cosmetics industry over the past 50 years [1][11]. Group 1: Historical Background - The "Changbai Snow" ginseng cream was first developed in 1974 in Jingyu County, known as the "hometown of ginseng," where local resources were utilized to create a skincare product that gained recognition and popularity [3][5]. - The product quickly gained acclaim, winning provincial quality awards from 1977 to 1984 and being exported to over a dozen countries, including Singapore and the United States [5]. Group 2: Technological Advancements - In June 2025, Jilin Province Lanpu Haoye Technology Co., Ltd. initiated a revival plan for the "Changbai Snow" brand, focusing on modern scientific methods to reinterpret the classic product [7]. - The company successfully developed "ginsenoside galacturonic acid oligosaccharide," which became the world's first ginseng-derived skincare acid, receiving approval from the National Medical Products Administration [7][9]. - A joint effort with the provincial drug inspection institute aims to establish the first industry standard for ginseng extract in cosmetics, enhancing product credibility [9]. Group 3: Product Development and Market Strategy - The production process of the new "Changbai Snow" cream incorporates low-temperature extraction and directed enzymatic hydrolysis to preserve active ingredients, ensuring consistent product quality through an intelligent production line [9]. - The brand is expanding its reach through e-commerce platforms and offline experience stores, transitioning from a reputation-based local brand to a scientifically-backed product appealing to a broader consumer base [11]. Group 4: Industry Significance - The journey of "Changbai Snow" reflects the evolution of the Chinese cosmetics industry from simple formulations to scientifically validated products, showcasing a blend of traditional wisdom and modern technology [11].

新生代父母的"精致育儿"模式，改变了中国儿童化妆品市场的需求格局与竞争叙事方式。 中国儿童化妆品产业较欧美日韩等发达市场起步较晚，产业发展面临基础数据库薄弱、儿童化妆品监管界定模糊、长期安全性研究缺乏等多项关键性挑 战。 1月30日，由国家市场监管总局发展研究中心牵头，深圳市计量质量检测研究院、广州海龟爸爸生物科技有限公司共同编制的《中国儿童化妆品行业发展 研究报告（2025）》（以下简称：报告）正式发布。 点击链接下载《报告》原文 中国儿童化妆品行业发展研究报告(2025).pdf 2025中国儿童化妆品行业发展研究报告发布现场 《报告》指出，当前中国儿童化妆品产业发展重点聚焦于法规标准体系的国际比较与本土化构建、儿童皮肤生理学与安全风险评估、市场细分与消费行为 洞察、产品研发与功效创新以及全生命周期监管科学五大领域，市场规模快速增长，行业规范化程度有待进一步提升。 2025中国儿童化妆品行业发展研究报告 回顾中国儿童化妆品行业的发展，20世纪80年代，中国婴童化妆品市场出现萌芽，经典老国货品牌填补了市场空白；20世纪90年代初，随着改革开放的持 续，国人的消费意识的增强和经济水平的提升，中国婴童化妆品市场 ...

Core Insights - Shanghai has approximately 10,000 industrial enterprises with an annual output value exceeding 20 million yuan, of which around 500 have an output value exceeding 1 billion yuan. By 2025, these "1 billion+" enterprises are expected to contribute over 60% of the output value of Shanghai's industrial enterprises and over 40% of industrial investment, serving as a stabilizing force for growth and investment [1] Group 1: Action Plan Overview - The action plan consists of "four major actions" with a total of 17 measures to support the achievement of its goals [2] - The "Structural Optimization and Upgrading Action" aims to enhance traditional advantageous industries, encouraging sectors like non-ferrous metals to strengthen specialty steel and expand light alloys [2] - The "Innovation and Fundamental Strengthening Action" supports enterprises in enhancing technological reserves, providing a one-time financial subsidy of 10 million yuan for companies investing over 10 million yuan annually in basic research [2] Group 2: Industry Support and Development - The "Resource Factor Support Action" focuses on talent, space, and funding, including policies to address industrial land lease renewals and promote low-interest loans for manufacturing [3] - By 2025, Shanghai's total industrial output value is projected to reach 4.07 trillion yuan, marking a return to the 4 trillion yuan level after two years [3] - Shanghai's industrial enterprises have seen a continuous decline in core cost factors, with direct industrial costs decreasing by 11.8 billion yuan in 2024 and an additional 10.33 billion yuan in 2025, leading to a cost of 81.5 yuan per 100 yuan of revenue, which is 4 yuan lower than the national average [3]

Group 1 - The core viewpoint of the article highlights the continuous improvement in drug safety and the high-quality development of the pharmaceutical industry in the province, with a significant increase in the number of production enterprises [1] - By the end of 2025, the province had a total of 2,618 "two products and one device" (drugs, cosmetics, and medical devices) production enterprises, representing a 53% increase compared to 2020 [1] - The drug safety inspection pass rate remains above 99%, with no major drug safety incidents reported [1] Group 2 - In 2025, the province approved 107 new drug approval numbers, with 60 new varieties passing the consistency evaluation for generic drugs [2] - The first class 1 innovative drug "Azvudine tablets" and the first antibody drug "Bevacizumab injection" were approved during the "14th Five-Year Plan" period [2] - The provincial drug regulatory authority aims to create a new ecosystem for pharmaceutical industry development through five major actions, focusing on political guidance, reform innovation, drug safety, industry ecology, and regulatory capacity enhancement [2]